Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
40.77
+2.25 (+5.85%)
Streaming Delayed Price
Updated: 12:24 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,488,695
Open
40.06
Bid (Size)
40.77 (1,900)
Ask (Size)
40.78 (1,300)
Prev. Close
38.52
Today's Range
39.89 - 41.23
52wk Range
35.12 - 81.44
Shares Outstanding
N/A
Dividend Yield
2.86%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
↗
Today 5:56 EDT
A rival company's trial results had a negative impact on Agios' stock this week.
Via
The Motley Fool
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
↗
April 23, 2026
Novo Nordisk stock has been stuck in a downward spiral for quite some time.
Via
The Motley Fool
Performance
YTD
-22.2%
-22.2%
1 Month
+10.5%
+10.5%
3 Month
-34.5%
-34.5%
6 Month
-23.4%
-23.4%
1 Year
-33.5%
-33.5%
More News
Read More
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
April 23, 2026
From
Equity Insider
Via
GlobeNewswire
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
↗
April 23, 2026
Via
The Motley Fool
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program
↗
April 21, 2026
Via
The Motley Fool
Topics
Stocks
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
↗
April 21, 2026
Via
The Motley Fool
Here's Why Agios Pharmaceuticals Crashed 23% Today
↗
April 20, 2026
Via
The Motley Fool
This Drug Stock Has Crushed the S&P 500 Over the Last Decade
↗
April 18, 2026
Via
The Motley Fool
Topics
Intellectual Property
Stocks
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
↗
April 17, 2026
Via
MarketBeat
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
↗
April 17, 2026
Via
The Motley Fool
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
↗
April 16, 2026
Via
The Motley Fool
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
↗
April 16, 2026
Via
The Motley Fool
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
↗
April 15, 2026
Via
The Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
↗
April 14, 2026
Via
The Motley Fool
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
April 09, 2026
Via
MarketMinute
Topics
Economy
Supply Chain
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
April 08, 2026
Via
MarketMinute
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
↗
April 08, 2026
Via
The Motley Fool
3 Absurdly Cheap Dividend Stocks to Buy in April 2026
↗
April 08, 2026
Via
The Motley Fool
Topics
Economy
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
April 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
April 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
Via
MarketMinute
Topics
Economy
World Trade
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?
↗
April 06, 2026
Via
MarketBeat
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
↗
April 04, 2026
Via
The Motley Fool
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
April 03, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
↗
April 03, 2026
Via
The Motley Fool
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 40.77
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 04/24/26 12:24 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.